Patents Issued in August 3, 2017
  • Publication number: 20170216426
    Abstract: In certain aspects the invention provides a selection of HIV-1 envelopes suitable for use as immunogens, and methods of using these immunogens to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize. In other embodiments, the immunogenic compositions and methods comprise at least one agent for transient immune response modulation during vaccination.
    Type: Application
    Filed: September 28, 2015
    Publication date: August 3, 2017
    Inventors: Barton F. HAYNES, Garnett KELSOE, Masayuki KURAOKA, M. Anthony MOODY, Hua-Xin LIAO, Laurent VERKOCZY
  • Publication number: 20170216427
    Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
    Type: Application
    Filed: July 23, 2015
    Publication date: August 3, 2017
    Inventors: Erica Bickerton, Sarah Keep, Paul Britton
  • Publication number: 20170216428
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses. The invention also provides methods of making the antigenic peptides and complexes of antigenic peptides and adjuvants. Methods of use of the pharmaceutical compositions are also provided.
    Type: Application
    Filed: September 12, 2016
    Publication date: August 3, 2017
    Applicant: Agenus Inc.
    Inventors: Alemseged Truneh, Daniel L. Levey, Annie Xiaoyan Mo, Kenneth P. Leclair, Ramesh S. Kashi, Aston Chuanliang Liu
  • Publication number: 20170216429
    Abstract: The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 3, 2017
    Applicant: NITTO DENKO CORPORATION
    Inventors: Takuya SHISHIDO, Daisuke ASARI, Kyohei MATSUSHITA, Mitsuhiko HORI
  • Publication number: 20170216430
    Abstract: The present invention aims to provide a composition for promoting immunity induction and a vaccine pharmaceutical composition which are universally usable for inducing immunity to various antigens and capable of exerting a high immunity inducing effect. The present invention relates to a composition for promoting immunity induction containing at least one nuclear receptor ligand and also relates to a vaccine pharmaceutical composition for inducing immunity containing an antigen and a composition for promoting immunity induction that is at least one nuclear receptor ligand.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 3, 2017
    Applicant: NITTO DENKO CORPORATION
    Inventors: Takuya SHISHIDO, Daisuke ASARI, Kyohei MATSUSHITA, Mitsuhiko HORI
  • Publication number: 20170216431
    Abstract: The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response.
    Type: Application
    Filed: October 1, 2015
    Publication date: August 3, 2017
    Applicant: NITTO DENKO CORPORATION
    Inventors: Takuya SHISHIDO, Daisuke ASARI, Kyohei MATSUSHITA, Katsuyuki OKUBO, Mitsuhiko HORI
  • Publication number: 20170216432
    Abstract: The present invention provides methods of treating, stabilizing or lessening the severity or progression of a disease or disorder associated with BTK.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 3, 2017
    Inventors: Tom Daniel, Kenichi Takeshita, Kenneth Foon, Jay Mei
  • Publication number: 20170216433
    Abstract: The present invention belongs to the fields of tumor therapy and molecular immunology, and provides an anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition thereof and use thereof. The monoclonal antibody of the present invention can block the binding of CLTA4 to B7, relieve the immunosuppression on the body by CTLA4, and activate T lymphocytes.
    Type: Application
    Filed: July 31, 2015
    Publication date: August 3, 2017
    Inventors: Baiyong Li, Yu Xia, Zhongmin Wang, Peng Zhang, Xinghua Pang
  • Publication number: 20170216434
    Abstract: This invention relates to methods of treating sickle cell disease with VLA-4 antagonists and methods for evaluating the responsiveness of patients having sickle cell disease to treatment with VLA-4 antagonists.
    Type: Application
    Filed: August 5, 2015
    Publication date: August 3, 2017
    Inventors: Patrick C. Hines, Moira M. Lancelot, Jennell C. Jackson, William E. Hobbs, II, Sriram Krishnamoorthy, David R. Light
  • Publication number: 20170216435
    Abstract: A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventor: Lewis S. Gruber
  • Publication number: 20170216436
    Abstract: Metallofullerene monocrystalline nanoparticles are used as tumor vascular disrupting agents. The monocrystalline nanoparticles are water-soluble metallofullerene nanoparticles with negative charges on their surfaces. The particle sizes range from 50 to 250 nanometers. The nanomaterials are able to absorb outside radiation energy, and transform it into heat energy. The volumes rapidly expand when temperature reaches a phase transformation point. For treatment, metallofullerene monocrystalline nanoparticles are administrated to a tumor-bearing organism via injection. The metallofullerene monocrystalline nanoparticles reach tumor sites via blood circulation, and are retained at the tumor sites. The monocrystalline nanoparticles of metallofullerene accumulate heat and the temperature increases under outside radiation energy.
    Type: Application
    Filed: July 29, 2014
    Publication date: August 3, 2017
    Inventors: Chunru Wang, Mingming Zhen, Chunying Shu, Taishan Wang, Jie Li, Guoqiang Zhang
  • Publication number: 20170216437
    Abstract: Systems and methods for releasing a material into an environment. The material may be encapsulated in a receptacle or otherwise packaged for movement into the environment. The receptacle with the material inside is introduced into the environment. A triggering causes release of the material from the receptacle into the environment.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: William C. Floyd, III, Roger D. Aines, Eric B. Duoss, John J. Vericella
  • Publication number: 20170216438
    Abstract: Photodynamic virus particles including a plant virus particle associated with a photosensitizing agent are described. Methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the photodynamic virus particles and illuminating a cancer-bearing region of the subject to activate the photodynamic virus particles are also described.
    Type: Application
    Filed: January 11, 2017
    Publication date: August 3, 2017
    Inventor: Nicole F. Steinmetz
  • Publication number: 20170216439
    Abstract: Disclosed herein are compositions, formulations, methods, devices and kits for modulating the production of cerumen, the treatment of ceruminosis, and the treatment of ceruminosis associated diseases or conditions. In these methods, the otic compositions and formulations are administered locally to an individual afflicted with ceruminosis and/or ceruminosis associated diseases, through direct application of the otic compositions and formulations to the external ear canal.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 3, 2017
    Inventors: Carl Lebel, Jeffrey S. Rosenbloom
  • Publication number: 20170216440
    Abstract: The invention relates to a potentiated antimicrobial agent for use in the treatment of a microbial infection, characterised in that said antimicrobial agent is used in association with a compound of formula (I), the mass ratio of compound of formula (I): antimicrobial agent varying between 8:1 and 1:10.
    Type: Application
    Filed: September 15, 2015
    Publication date: August 3, 2017
    Applicant: SEPTEOS
    Inventor: Nicolas TESSE
  • Publication number: 20170216441
    Abstract: The invention provides compositions and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. The kits of the invention include a first container having a first active agent and a second container having at least one second inactive agent. The kits of the invention are also useful for compounding veterinary pharmaceuticals.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 3, 2017
    Applicant: CutisPharma, Inc.
    Inventor: Indu Muni
  • Publication number: 20170216442
    Abstract: An erodible anhydrous film useful in delivering active agents to a surface including keratinous surfaces, and hard or soft surfaces is disclosed. The erodible anhydrous film contains polyethylene oxide in combination with a support polymer, and optionally, other additives for skin care, fabric care, or hard surface cleaning. The erodible anhydrous film is useful when used as a comfort strip for enhancing shaving.
    Type: Application
    Filed: September 30, 2015
    Publication date: August 3, 2017
    Inventors: Paul Burgio, George Kellett, Robert McCormack, Rooma Mehta, James S Smith
  • Publication number: 20170216443
    Abstract: The present disclosure provides derivatives of abiraterone, non-covalently bound complexes of the abiraterone derivatives with serum albumin, pharmaceutical compositions of the same, and methods of use thereof. The non-covalently bound complexes are significantly more water-soluble than abiraterone and are useful for the treatment of a disease or condition that can benefit from CYP17 inhibition, such as prostate cancer.
    Type: Application
    Filed: June 26, 2015
    Publication date: August 3, 2017
    Inventor: Qun SUN
  • Publication number: 20170216444
    Abstract: An object is to provide a preparation for forming emboli highly safe in a living body and capable of retaining and controlled-releasing an anticancer agent, occluding a blood vessel when injected into the blood vessel, unlikely to be washed out and having a controlled decomposition time (i.e., occludes a blood vessel for a while and quickly decomposes to prevent the necrosis of the entire tissues when the function is completed). The preparation for forming emboli according to the present invention comprises a solution comprising a phenolic hydroxyl group-modified polymer represented by the following formula (1): wherein P is a biocompatible polymer, A is a single bond or an —OCO—C2-C4-alkenylene group, a —CONH—C1-C4-alkylene group or an —HNCO—C1-C4-alkylene group, and X is hydrogen or a C1-C3-alkoxy group, a solution comprising at least one selected from a peroxidase, a laccase, a tyrosinase, a catalase and an iron porphyrin complex and a solution comprising hydrogen peroxide.
    Type: Application
    Filed: October 19, 2015
    Publication date: August 3, 2017
    Inventors: Tsutomu TAMAI, Takayuki TAKEI, Akio IDO, Masahiro YOSHIDA, Shinji SAKAI
  • Publication number: 20170216445
    Abstract: The present invention generally relates to carriers including polymers and lipids that comprise a CXCR4 inhibiting moiety. More specifically, these carriers are biodegradable and can be bioreducible polymers that comprise a CXCR4 inhibiting moiety. These carriers can be suitable for delivery of nucleic acids to cells. These carriers and pharmaceutical compositions comprising these carriers can be used to treat various conditions including cancers and inflammation conditions.
    Type: Application
    Filed: January 11, 2017
    Publication date: August 3, 2017
    Inventors: David Oupicky, Jing Li
  • Publication number: 20170216446
    Abstract: There is provided a polymer-flavonoid conjugate, or a pharmaceutically acceptable salt thereof, uses thereof, and methods of making thereof. The disclosed polymer-flavonoid conjugates may be useful in the therapeutic and/or prophylactic treatment of a joint condition in a subject.
    Type: Application
    Filed: May 15, 2015
    Publication date: August 3, 2017
    Inventors: Motoichi KURISAWA, Fan LEE
  • Publication number: 20170216447
    Abstract: The present invention relates to combination therapy with drugs, such as Bruton's tyrosine kinase inhibitors or PI3K inhibitors, with antibodies or ADCs against HLA-DR. Where ADCs are used, they preferably incorporate SN-38 or pro-2PDOX. The ADC may be administered at a dosage of between 1 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Inventors: David M. Goldenberg, Thomas M. Cardillo
  • Publication number: 20170216448
    Abstract: The present application relates to an inhibitor of fusion between a viral membrane from an enveloped virus and a cell membrane, where the viral membrane comprises a fusion mediating protein including a C-terminal peptide. The inhibitor comprises the C-terminal peptide of the fusion mediating protein from an enveloped virus and tocopherol or a derivative or pharmaceutically acceptable salt thereof attached to the C-terminal peptide. Also disclosed is a pharmaceutical composition including the inhibitor as well as methods of inhibiting viral fusion, blocking viral spread, and preventing or treating viral infection, with the inhibitor or pharmaceutical composition.
    Type: Application
    Filed: May 7, 2015
    Publication date: August 3, 2017
    Applicants: Cornell University, Inserm
    Inventors: Matteo POROTTO, Anne MOSCONA, Branka HORVAT, Cyrille MATHIEU
  • Publication number: 20170216449
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Application
    Filed: February 11, 2017
    Publication date: August 3, 2017
    Applicant: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Publication number: 20170216450
    Abstract: The invention provides a novel system of nano-assemblies and related method for delivery of therapeutic, diagnostic or imaging agent to biological sites. The compositions and methods of the invention enable the syntheses of novel polymeric nano-assemblies (nanoparticles) under non-emulsion conditions with the incorporation of hydrophobic guest molecules. The versatilities and advantages of the polymer nanoparticles of the invention include: (i) the guest molecules (e.g.
    Type: Application
    Filed: February 7, 2017
    Publication date: August 3, 2017
    Inventor: Sankaran Thayumanavan
  • Publication number: 20170216451
    Abstract: The present invention relates to the preparation End use of therapeutic compounds for the treatment of diseases at specific subcellular target areas such as specific cellular organelles. In particular, the therapeutic compounds of the invention are specific for modifying enzyme activity within targeted organelles or structures of cells and tissues. Subcellular organelles and structures that may be specifically targeted by compounds of the present invention include lysosomes, autophagasomes, the endoplasmic reticulum, the Golgi complex, peroxisomes, the nucleus, membranes and the mitochondria.
    Type: Application
    Filed: April 3, 2017
    Publication date: August 3, 2017
    Inventors: John Joseph Naleway, Fiona Karen Harlan, Jason Scott Lusk
  • Publication number: 20170216452
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise a substituted cysteine for site-specific conjugation.
    Type: Application
    Filed: November 21, 2016
    Publication date: August 3, 2017
    Inventors: Dangshe MA, Kimberly Ann MARQUETTE, Edmund Idris GRAZIANI, Puja SAPRA, Lawrence Nathan TUMEY, Nadira Anarkali PRASHAD, Kiran Manohar KHANDKE, Eric M. BENNETT, Lioudmila TCHISTIAKOVA
  • Publication number: 20170216453
    Abstract: This document provides methods and materials related to treating lymphomas. For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-CD20 polypeptide antibody complexes) to treat lymphomas are provided.
    Type: Application
    Filed: March 7, 2017
    Publication date: August 3, 2017
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Publication number: 20170216454
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Application
    Filed: July 17, 2015
    Publication date: August 3, 2017
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • Publication number: 20170216455
    Abstract: The invention relates to branched polymers which find use in gene therapy applications as nucleic acid transfection agents. In particular, the invention provides biodegradable, hyperbranched polymers which can be used in gene delivery and which provide improved transfection efficiencies which at the same time are safe and non-toxic.
    Type: Application
    Filed: August 6, 2015
    Publication date: August 3, 2017
    Applicant: National University of Ireland, Galway
    Inventors: Wenxin WANG, Dezhong ZHOU
  • Publication number: 20170216456
    Abstract: Provided herein are methods for facilitating or inducing stable transgene integration and expression in a proliferating cell, comprising administering to the cell (i) a recombinant AAV (rAAV) vector comprising the transgene flanked by transposon-derived inverted terminal repeat sequences, which sequences are in turn flanked by AAV-derived inverted terminal repeat regions, and (ii) a source of a transposase that recognises said transposon-derived inverted terminal repeat sequences and directs the genomic integration of the transgene into the genome of the proliferating cell. Also provided are methods and transgene delivery systems for the treatment or prevention of diseases affecting, associated with or characterised by proliferating cells, including paediatric liver diseases, bone marrow diseases and cancer.
    Type: Application
    Filed: March 23, 2015
    Publication date: August 3, 2017
    Inventors: Ian Alexander, Sharon Cunningham, Andras Nagy
  • Publication number: 20170216457
    Abstract: Disclosed are nanoparticles that are introduced into cells and express a specific protein and a manufacturing method thereof. More particularly, the present invention relates to mRNA nanoparticles, which increase the expression of a specific protein capable of stimulating the cellular immune system to induce cellular immune responses and are thus applicable to treat a variety of diseases, do not require passage across the nuclear envelope because a desired gene is delivered not as plasmid DNA itself but in the form of mRNA, thus improving the efficiency of protein expression, and the nanoparticles are generated through a one-step process with a relatively small amount of plasmid DNA via rolling circle transcription (RCT), thereby providing a simple and economical process for gene delivery. The present invention is also concerned with such mRNA nanoparticles.
    Type: Application
    Filed: October 1, 2015
    Publication date: August 3, 2017
    Inventors: Jong-Bum LEE, Hye-Jin KIM
  • Publication number: 20170216458
    Abstract: The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAA9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Brian K. Kaspar, Arthur Burghes, Paul Porensky
  • Publication number: 20170216459
    Abstract: The invention provides methods and composition developed to be used with imaging techniques and useful for diagnosis and monitoring the pain generator(s) of axial pain with or without radiculopathy and methods for screening therapeutic compounds potentially useful for treating axial pain with or without radiculopathy. Alternatively, degenerated discs can be monitored and treated before occurrence of a pathological pain condition. Pain markers and markers of degeneration include markers of neuronal, vascular, immune and matrix elements.
    Type: Application
    Filed: April 11, 2017
    Publication date: August 3, 2017
    Inventors: William F. McKay, Jeffrey M. Gross, Hai Trieu, Josee Roy, Susan J. Drapeau, Michael J Schendel, Andrew J. Lowenthal Walsh
  • Publication number: 20170216460
    Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.
    Type: Application
    Filed: May 31, 2016
    Publication date: August 3, 2017
    Inventors: Kwangmeyung KIM, Ju Hee RYU, Ick Chan KWON, Man Kyu SHIM, Hong Yeol YOON
  • Publication number: 20170216461
    Abstract: The present invention discloses a preparation technique of composite nanodots based on carbon nanodots, and their use in the field of fluorescent imaging, wherein, the main components of the composition are carbon nanodots, which are material with superior biocompatibility characteristics, and supporting component is methylene blue, and particle diameter range is 100-500 nanometers, and the zeta potential is ?35 to 10 millivolts. The above said techniques for preparation of composite nanodots are safe, quick and simple, low cost, and easy to perform for industrialized production. Composite carbon nanodots have good biocompatibility and safety, high fluorescence imaging sensitivity, and they are promising in gaining wider use in the fields of biomedical imaging, targeting diagnosis and therapy, drug screening and optimization, and in vivo labelling and tracing, and have potential value in personalized medicine.
    Type: Application
    Filed: February 1, 2016
    Publication date: August 3, 2017
    Inventors: Zhe Liu, Qien Xu, Yuanhui Song, Yihong Li
  • Publication number: 20170216462
    Abstract: A method for producing a liquid pharmaceutical preparation which contains a complex consisting of DOTA and gadolinium and a base such as L-lysine or meglumine, includes the following steps: a) An aqueous solution containing free DOTA, free gadolinium and a base such as L-lysine or meglumine is produced. b) The yield of free DOTA and free gadolinium is determined in the solution obtained according to step a). c) Free gadolinium and/or free DOTA is added in order to adjust a stoichiometric excess of free DOTA in the solution. d) The complexation is executed at an increased temperature. e) Additional base such as L-lysine or meglumine is added in order to adjust the pH value. f) The final volume of the preparation is adjusted.
    Type: Application
    Filed: June 15, 2015
    Publication date: August 3, 2017
    Inventors: Stefan WELZIG, Raffael SCHUECKER, Beate KAELZ, Jozsef GUNGL, Klaus GERDES, Roswitha BRAUNRATH
  • Publication number: 20170216463
    Abstract: A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Ralph Weissleder, Hakho Lee, Tae-Jong Yoon
  • Publication number: 20170216464
    Abstract: Nanoparticles described as metal-encapsulated carbonaceous dots or M@C-dots are disclosed. Also disclosed are specific M@C-dots with gadolinium, so called Gd@C-dots. These nanoparticles are biologically inert and preclude the release of metal in biological environments. In addition, despite a dimension exceeding the commonly recognized threshold for renal clearance, the disclosed nanoparticles can be efficiently cleared via urine after systematic injection. Methods of making and using such nanoparticles are also disclosed.
    Type: Application
    Filed: July 30, 2015
    Publication date: August 3, 2017
    Inventors: Jin Xie, Hongmin Chen, Geoffrey D. Wang
  • Publication number: 20170216465
    Abstract: Neurokinin-1 (NK-1) receptor-binding agent delivery conjugates, compositions comprising NK-1 receptor-binding agent delivery conjugates, and methods for making and administering NK-1 receptor-binding agent delivery conjugates are provided. A conjugate may include an NK-1 receptor-binding moiety, a linker group containing at least one linker selected from the group of a releasable linker and a spacer linker, and an active agent linked to the linker group. The active agent may be selected from the group of fluorophore-containing compounds, radionuclide-containing compounds, and therapeutic agents for treatment of tumor cells characterized by over-expression of the NK-1 receptor.
    Type: Application
    Filed: August 7, 2015
    Publication date: August 3, 2017
    Inventors: Ananda Kumar KANDULURU, Philip S. LOW
  • Publication number: 20170216466
    Abstract: A sterilizer device adapted to deliver ultraviolet (UV) light to reduce the bacterial burden of skin incisions or wound surfaces in animals and humans. In one embodiment, the sterilizer device includes a microprocessor that is connected to a control unit, a user interface, an audio input/output, a connectivity module, a power source, a timer, a vibrating alert, a sensor for detecting a distance between a treatment area and the device, and a memory. The control unit is connected to a UV light source and an accelerometer. The user interface includes a display screen and control buttons. The audio input/output includes a speaker and a microphone. The connectivity module includes a USB port and/or a wireless connection. The sterilizer device is configured such that when a user activates one or more of the control buttons, the UV light source delivers a safe dose of UV-C that can kill bacteria.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 3, 2017
    Applicant: ONE HEALTH LABS, INC.
    Inventors: Mauricio Dujowich, Jennifer Jean Bentley
  • Publication number: 20170216467
    Abstract: Methods and systems for sterilizing a room are disclosed, including using a laser positioned within a housing to generate a pulsed laser beam; and intercepting the pulsed laser beam with a scattering optical element to substantially isotropically scatter the radiation of the pulsed laser beam outside the housing to sterilize the room. The scattering optical element comprises a hollow fused silica bulb filled with solid fused silica spheres or a fiber optic bundle and in some embodiments the scattering optical element is rotated. The pulsed laser beam comprises a wavelength ranging between about 200 nm to about 320 nm and in some embodiments comprises nanosecond or picosecond light pulses. Other embodiments are described and claimed.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: John Taboada, John Martin Taboada
  • Publication number: 20170216468
    Abstract: A Sterilization Unit includes: a UV-C radiation source configured to emit UV-C radiation; and a room partition selectably configurable between two or more different partition geometrics and configured, in each of the two or more different partition geometrics, to (a) physically separate floor space of a room into sterilization target area and a non-target area, and (b) direct the UV-C radiation to the target area from at least two different directions while shielding the non-target area from the UV-C radiation.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 3, 2017
    Applicant: PurpleSun, Inc.
    Inventors: Luis Fernando Romo, Arto Cinoglu, David Moses
  • Publication number: 20170216469
    Abstract: The invention relates to a method and to a device for quickly decontaminating and sterilizing preferably thermolabile goods using a plasma gas that is preferably generated from air as a process gas, with the subsequent humidification of said plasma gas with water. The method comprises the following steps: generating a plasma from air as the process gas, which forms reactive nitrogen and oxygen species; oxidizing NO to form NO2 at temperatures below 400° C. so that a plasma-activated gas mixture forms having an NO2 content of at least 0.3%; bringing said plasma-activated gas mixture in contact with water in one or more of the states of aggregation thereof; bringing the latter gas mixture in contact with the objects to be decontaminated or sterilized.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Applicant: LEIBNIZ-INSTITUT FUER PLASMAFORSCHUNG UND TECHNOLOGIE E.V., INP GREIFSWALD
    Inventors: Udo Krohmann, Joerg Ehlbeck, Torsten Neumann, Uta Schnabel, Mathias Andrasch, Wolfram Lehmann, Klaus-Dieter Weltmann
  • Publication number: 20170216470
    Abstract: A lighting device with a lighting function includes a coating layer coated onto the outer surface of a main body, and the coating layer is made of an antiviral material, so that the main body of the lighting device is coated with an antiviral material mainly composed of titanium dioxide and nanosilver to provide the self-cleaning and deodorizing effects, and the advantages of resisting viruses and bacteria, removing pollutants from the environment, and preventing mildews and algae effectively.
    Type: Application
    Filed: September 20, 2016
    Publication date: August 3, 2017
    Inventors: CHIAO-AN HSIAO, YU-HSIU LU, CHUN-HUI WU
  • Publication number: 20170216471
    Abstract: The disclosed invention relates to a two-part liquid composition for cleaning and disinfecting a substrate, comprising: (A) a disinfectant medium comprising peracetic acid; and (B) a supplemental medium comprising a non-enzymatic cleaner, a corrosion inhibitor, and a chelator. The supplemental medium (B) may further comprise an enzymatic cleaner, a surfactant, a buffer, a pH modifier, or a mixture of two or more thereof. The substrate may be a medical device, for example, an endoscope.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: Phillip P. Franciskovich, Donald G. Rosenhamer, Kathleen A. Fix
  • Publication number: 20170216472
    Abstract: Methods and systems are provided which project germicidal light from a lamp toward an individual donned in outerwear to disinfect the outerwear. In specific embodiments, germicidal light is projected toward an individual situated greater than approximately 1 foot from the light source. Some systems include sensor/s for detecting presence of an individual within a target area a set distance from the disinfection apparatus comprising the light source and program instructions for commencing operation of the disinfection apparatus based on information from the sensor/s. In addition or alternatively, some systems include reflective panel/s exhibiting greater than approximately 85% reflectance.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 3, 2017
    Inventors: Mark A. Stibich, Sarah E. Simmons, Edward C. Guerrero, JR., Paul P. Froutan
  • Publication number: 20170216473
    Abstract: Sterilization units and systems and related assemblies, devices, and methods are disclosed. The sterilization units may be mobile and used in a variety of locations. The sterilization units and systems use germicidal ultraviolet-C light to kill or render non-viable bacteria and viruses. The various sterilization units and systems disclosed herein may have improved ultraviolet light distribution and/or improved ability to direct and focus the ultraviolet light in a desired area. The sterilization units and systems may optionally be made of non-magnetic materials such that the sterilization units and systems may be used in the vicinity of MRI equipment without causing complications or damage to the MRI equipment.
    Type: Application
    Filed: April 19, 2017
    Publication date: August 3, 2017
    Inventor: Alan Rizzone
  • Publication number: 20170216474
    Abstract: The present invention is directed to a digital aroma system that provides a scented air on demand to various devices in various forms and user held devices including: remote controls, video game controllers and mobile computing devices. Dry fragrance infused substrates are contained in fragrance cartridges that are removably mounted in a cassette that is connected to a manifold that has airway passages that are connected to fans or pumps that are controlled by a computer processor. In response to a fragrance control signal or a fragrance trigger, the processor can selectively direct scented air having a specified fragrance to a system user.
    Type: Application
    Filed: July 25, 2016
    Publication date: August 3, 2017
    Inventor: Keith Kelsen
  • Publication number: 20170216475
    Abstract: A storage apparatus according to an embodiment may include a body having a storage space of storage products and an air purifying module coupled to the body. The air purifying module may include a light emitting diode part disposed along a passage of air to provide ultraviolet light, and a filter part disposed adjacent to the light emitting diode part.
    Type: Application
    Filed: April 13, 2017
    Publication date: August 3, 2017
    Inventors: Jung Yeol Park, Young Hwan Son, Seong Min Lee, Jae Son Yi, Jong Hyun Koo, Sang Hee Cho, Ju Won Yoo, Sung Lim Cho, Jong Rack Kim